Bristol Myers Squibb is constructing a new 244,000 square foot cell therapy manufacturing facility in Devens, Massachusetts. The company plans to hire several hundred employees over the next few years to support the new operations.
The new cell therapy facility will be located on Bristol Myers Squibb’s current 89-acre Devens campus that supports process development, clinical manufacturing and commercial manufacturing for biologics medicines, including an immuno-oncology medicine. The project is part of significant investment to support clinical and commercial manufacturing of transformative cell therapies for patients with aggressive hematological cancers.
“Bristol Myers Squibb is at the forefront of manufacturing innovations, and we are proud that our new cell therapy facility in the Boston area will include many next generation technologies and the latest integrated digital systems,” said Ann Lee, Ph.D., head, Cell Therapy Development & Operations, Bristol Myers Squibb. “Bristol Myers Squibb has designed a reliable manufacturing and global supply chain network comprising internal manufacturing facilities, which include Bothell, Washington, Summit, New Jersey, and Warren, New Jersey, in the U.S., as well as external manufacturing facilities in the U.S., Europe and Japan. Expanding our global footprint is critical to supplying these transformational products to patients around the world.”
The Devens site is the latest investment from Bristol Myers Squibb as the company expands its robust global manufacturing network. The Devens site will be equipped to enable quick ramp up of capacity for clinical and commercial cell therapy products. BMS also operates two R&D facilities in Cambridge, Massachusetts, and will be bringing those two sites together into a new building at Cambridge Crossing in 2023.